BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37650153)

  • 1. Predictive Models for Colon Adenocarcinoma Diagnosis, Prognosis, and Immune Microenvironment Based on 2 Hypoxia-Related Genes: KDM3A and ENO3.
    Kong C; Zheng L; Fang S; Chen M; Lin G; Qiu R; Zhao Z; Chen W; Song J; Yang Y; Ji J
    Technol Cancer Res Treat; 2023; 22():15330338231195494. PubMed ID: 37650153
    [No Abstract]   [Full Text] [Related]  

  • 2. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.
    Bai Z; Yan C; Nie Y; Zeng Q; Xu L; Wang S; Chang D
    J Gene Med; 2024 Jan; 26(1):e3620. PubMed ID: 37973153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the six-hormone secretion-related gene signature as a prognostic biomarker for colon adenocarcinoma.
    Jia X; Zhang T; Lv X; Du H; Sun Y; Guan Y
    Cancer Biomark; 2023; 38(4):523-535. PubMed ID: 38143338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
    Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
    [No Abstract]   [Full Text] [Related]  

  • 6. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
    Lin A; Gu T; Hu X; Zhang J; Luo P
    J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing a RiskScore Model based on Angiogenesis-related lncRNAs for Colon Adenocarcinoma Prognostic Prediction.
    Li X; Lei J; Shi Y; Peng Z; Gong M; Shu X
    Curr Med Chem; 2024; 31(17):2449-2466. PubMed ID: 37961859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel glycolysis-related gene signature for predicting the survival of patients with colon adenocarcinoma.
    Yi K; Wu J; Tang X; Zhang Q; Wang B; Wang F
    Scand J Gastroenterol; 2022 Feb; 57(2):214-221. PubMed ID: 34644216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.
    Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J
    Front Immunol; 2022; 13():881359. PubMed ID: 35911752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma.
    Gao H; Xing F
    BMC Med Inform Decis Mak; 2022 Oct; 22(1):277. PubMed ID: 36273131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-Related Gene-Based Signature Can Evaluate the Tumor Immune Microenvironment and Predict the Prognosis of Colon Adenocarcinoma Patients.
    He X; Ding J; Cheng X; Xiong M
    Int J Gen Med; 2021; 14():9853-9862. PubMed ID: 34938106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of 9 Gene Signatures by WGCNA to Predict Prognosis for Colon Adenocarcinoma.
    Yang M; He H; Peng T; Lu Y; Yu J
    Comput Intell Neurosci; 2022; 2022():8598046. PubMed ID: 35392038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To explore the prognostic characteristics of colon cancer based on tertiary lymphoid structure-related genes and reveal the characteristics of tumor microenvironment and drug prediction.
    Wang Z; Niu D
    Sci Rep; 2024 Jun; 14(1):13555. PubMed ID: 38867070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.
    Wang H; Wang W; Wang Z; Li X
    Front Immunol; 2023; 14():1291859. PubMed ID: 38143740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Interferon Gamma-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Xie Y
    Front Oncol; 2022; 12():876660. PubMed ID: 35747790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of PI4K2A predicted poor prognosis of colon adenocarcinoma (COAD) and correlated with immunity.
    Huang X; Cao Y; Bao P; Zhu B; Cheng Z
    Cancer Med; 2023 Jan; 12(1):837-851. PubMed ID: 35634680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and verification of a combined immune- and cancer-associated fibroblast related prognostic signature for colon adenocarcinoma.
    Wei J; Ge X; Qian Y; Jiang K; Chen X; Lu W; Yang H; Fu D; Fang Y; Zhou X; Xiao Q; Tang Y; Ding K
    Front Immunol; 2024; 15():1291938. PubMed ID: 38312843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of the prognosis, tumor microenvironment, and immunotherapy response of SDHs in colon adenocarcinoma.
    Nan H; Guo P; Fan J; Zeng W; Hu C; Zheng C; Pan B; Cao Y; Ge Y; Xue X; Li W; Lin K
    Front Immunol; 2023; 14():1093974. PubMed ID: 36949947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.